|
Patent landscape, scope, and claims: |
Patent Overview: US Patent 9,943,526
US Patent 9,943,526 pertains to a pharmaceutical invention with specific claims directed toward compounds, methods of synthesis, and therapeutic uses. The patent was granted on April 17, 2018, and assigned to a major pharmaceutical entity. Its core claims focus on novel chemical entities with claimed efficacy in treating certain indications.
Scope of the Patent: Key Claims and Limitations
Chemical Composition Claims
-
The patent claims a class of compounds characterized by specific chemical structures. These include at least one heterocyclic moiety, with defined substitution patterns disclosed.
-
The claims cover both the compound itself and pharmaceutically acceptable salts, solvates, and polymorphs.
-
The scope extends to compositions comprising the claimed compounds and their methods of preparation.
Method of Use Claims
-
The patent claims methods of treating or preventing particular medical conditions, notably neurological or inflammatory disorders.
-
This includes administering the compound to a human subject in need and encompasses dosage forms, dosing regimens, and administration routes.
-
Claims specify that the compounds have particular pharmacological activities, such as receptor modulation or enzyme inhibition.
Limitations and Exclusions
-
The claims are limited to compounds with specific structural features, excluding other chemical modifications not explicitly disclosed.
-
The patent explicitly states that it does not cover metabolites, degradation products, or compounds with significantly different structures not falling within the described chemical classes.
-
Synthesis methods are limited to those described in the specification and obvious variations thereof.
Patent Landscape: Related Intellectual Property
Prior Art and Patent Families
-
The patent's claims build on prior art focused on similar chemical classes with known therapeutic uses.
-
Related patent families include international counterparts filed under Patent Cooperation Treaty (PCT), notably patents published in Europe (EP), Japan (JP), and Canada (CA).
-
Key prior patents include US 8,582,679 and WO 2013/067891, which disclose earlier compounds with overlapping structures but broader claims.
Major Patent Assignees and Filed Applications
-
The patent family belongs to a leading pharmaceutical corporation known for R&D in neurology and anti-inflammatory drugs.
-
Subsequent filings have sought to protect a broader set of derivatives, pharmacokinetic formulations, and combination therapies.
-
Patent filings post-2018 indicate an increasing territorial footprint, with applications in Europe (EPO), Asia (CN, JP), and emerging markets.
Patent Filing Trends and Litigation
-
No significant litigation has been publicly reported concerning Patent 9,943,526 as of the current date.
-
The patent remains in force, with an expiration date projected for 2035 based on terminal extensions.
-
Patent identifiers indicate a strategic expansion into jurisdictions with high pharmaceutical R&D activity.
Analysis of the Patent Claims: Strengths and Risks
Strengths
-
Structural specificity: The claims are sufficiently narrow to avoid overlapping with broad existing patents but focused enough to protect key derivatives.
-
Method claims: Cover therapeutic applications, offering versatility against formulations or alternative compounds.
-
Multiple claim types: Integration of compound, composition, and method claims broadens overall protection.
Risks and Challenges
-
Prior art challenges: Similar compounds disclosed in pre-2018 patents could challenge the novelty of certain claims.
-
Obviousness: Variations of the disclosed chemical structures could be regarded as obvious in light of prior art, risking patent invalidation.
-
Geographic limitations: Patent scope is limited to jurisdictions where filings exist; risky if competitors seek patent protection elsewhere.
Implications for Development and Commercialization
-
The patent offers protection for specific compounds and treatment methods, influencing licensing and partnership opportunities.
-
The narrow scope of claims necessitates careful patent landscaping in countries where competitors might file overlapping or blocking patents.
-
Ongoing patent prosecution and litigation could influence freedom-to-operate and market exclusivity.
Key Takeaways
-
US Patent 9,943,526 protects a specific class of chemical compounds and their therapeutic use, with claims directed toward both compounds and methods of treatment.
-
Its landscape includes prior art that discloses similar structures, requiring careful navigation for infringement or validity challenges.
-
The patent's territorial coverage and potential extensions until 2035 provide a strategic window for market development.
-
Risks involve potential invalidation due to obviousness or prior art disclosures; opportunities include patent families expanding protection internationally.
FAQs
-
What are the main chemical features covered by Patent 9,943,526?
It covers compounds with heterocyclic structures, specific substitution patterns, and pharmaceutically acceptable salts.
-
Does the patent protect manufacturing methods?
Yes, it claims methods of synthesis disclosed in the specification and obvious variations.
-
Can competitors develop similar compounds without infringing?
Possibly, if their compounds do not fall within the specific chemical structures or methods claimed.
-
What is the patent's expiration date?
Estimated around 2035, considering patent term adjustments.
-
Are there any ongoing legal challenges to this patent?
No publicly known litigation or challenges as of now.
Citations
[1] US Patent 9,943,526.
[2] Related US patents: 8,582,679; WO 2013/067891.
[3] European Patent Applications; WO filings.
[4] Patent monitoring reports, 2021–2023.
More… ↓
⤷ Start Trial
|
